```markdown
---
application_number: 208419Orig1s000
letter_type: Complete Response
applicant_name: Actavis LLC
parent_company: Teva Pharmaceuticals U.S.A. Inc.
contact_person: Cory Wohlbach
contact_title: Senior Director, Regulatory Affairs
contact_address: 400 Interpace Parkway, Morris Corporate Center III, Parsippany, NJ 07054
product_name: Pemetrexed Injection 25 mg/mL
application_received_date: 2016-12-23
complete_response_date: 2018-01-24
original_action_letter_date: 2017-09-26
division: Division of Oncology Products 2
office: Office of Hematology and Oncology Products
review_center: Center for Drug Evaluation and Research
signatory: Joseph Gootenberg, M.D.
signatory_title: Deputy Director
regulatory_project_manager: Rebecca Cohen
rpm_phone: 240-402-4998
---

## Critical Data

- **Application Number:** 208419Orig1s000  
- **Letter Type:** Complete Response  
- **Applicant:** Actavis LLC (subsidiary of Teva Pharmaceuticals U.S.A. Inc.)  
- **Product Name:** Pemetrexed Injection 25 mg/mL  
- **Date of Original NDA Submission:** December 23, 2016  
- **Complete Response Submission Date:** January 24, 2018  
- **Previous Action Letter Date:** September 26, 2017  
- **FDA Division:** Division of Oncology Products 2  
- **FDA Office:** Office of Hematology and Oncology Products  
- **Review Center:** Center for Drug Evaluation and Research  
- **Signatory:** Joseph Gootenberg, M.D., Deputy Director  
- **Regulatory Health Project Manager:** Rebecca Cohen  
- **Contact Phone:** (240) 402-4998  

---

# CENTER FOR DRUG EVALUATION AND RESEARCH  
**APPLICATION NUMBER:** 208419Orig1s000  
**OTHER ACTION LETTERS**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
Food and Drug Administration  
Silver Spring MD 20993

**NDA 208419**  
**COMPLETE RESPONSE**

Actavis LLC, an indirect, wholly-owned subsidiary of Teva Pharmaceuticals U.S.A. Inc.  
Attention: Cory Wohlbach  
Senior Director, Regulatory Affairs  
400 Interpace Parkway  
Morris Corporate Center III  
Parsippany, NJ 07054  

---

Dear Mr. Wohlbach:

Please refer to your New Drug Application (NDA) dated and received December 23, 2016, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Pemetrexed Injection 25 mg/mL.

We acknowledge receipt of your amendment dated January 24, 2018, which constituted a complete response to our September 26, 2017, action letter.

We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form. We have described our reasons for this action below and, where possible, our recommendations to address these issues.

---

## CHEMISTRY, MANUFACTURING, AND CONTROLS

### Drug Product

1. Provide updated drug product release and stability specifications for all three presentations of Pemetrexed Injection to reflect formulation changes. Include an assay test for the new excipient component.

2. Provide updated stability data for three batches for each Pemetrexed Injection presentation from Sindan and Actavis Italy sites:
    - 12-months long-term
    - 6-months accelerated stability (3 batches per presentation)
    - For alternate site: 3-month accelerated data on 3 batches if quality is comparable

3. Submit summary of bacterial endotoxins testing study using the kinetic-chromogenic method at S.C. Sindan-Pharma S.R.L. Include:
    - Sample preparation
    - Dilutions tested
    - Results
    - Proposed routine testing dilution

4. Provide sterility test method suitability data from Actavis Italy S.p.A. and S.C. Sindan-Pharma S.R.L. Include:
    - Description of studies
    - Actual test results

5. Provide scientific rationale or microbiological study to validate safety of specified post-dilution storage conditions (14 days refrigerated, limited room temp duration).

---

## PRESCRIBING INFORMATION

6. Labeling comments deferred. Review PLR and Pregnancy & Lactation Regulations. If revised:
    - Use SRPI checklist
    - Submit in **SPL format** via FDA guidelines:  
      [SPL Guidance](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)

---

## SAFETY UPDATE

Submit complete safety update per 21 CFR 314.50(d)(5)(vi)(b), including nonclinical and clinical data across all uses.

### Required Details:

7. Fully describe any notable safety profile changes.

8. Adverse events:
    - Use original submission format
    - Include new and combined safety data tabulations
    - Provide comparison tables
    - Separate tables for other indications

9. Update on premature discontinuation causes and patterns.

10. Include:
    - Case report forms
    - Narratives for deaths, serious AEs, discontinuations

11. Describe changes in common but less serious AE incidence.

12. Submit updated trial exposure data (subjects, person-time, etc.).

13. Update global safety data with estimated usage in each country.

14. Include English versions of newly approved foreign labeling.

---

## OTHER

You must **resubmit within one year** or action will be taken under 21 CFR 314.65.

- Resubmission must:
  - Fully address deficiencies
  - Be labeled **"RESUBMISSION"** clearly on cover
  - Be clearly identified as a **complete response**

> **Partial responses are not accepted for review restart.**

To request a meeting, follow guidance:  
[Formal Meeting Guidance (Dec 2017)](https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM590547)

> **The drug product cannot be legally marketed until we notify approval in writing.**

---

## ADDITIONAL COMMENTS (Not Approvability Issues)

### General Container & Carton Labeling

15. Update statement on principal display panel to:  
    - **“Must dilute before intravenous infusion”**

16. **Bold** the “Refrigerate at 2°–8°C” storage condition on side panel.

### Container Labels

17. Ensure barcode has adequate whitespace as per 21 CFR 201.25(c)(1)(i).  
    - For Italy-manufactured product, consider enlarging whitespace.

### Carton Labeling

18. Standardize barcode panel placement:
    - Romanian - bottom panel
    - Italian - side panel  
    → Achieve consistency across sites

19. Remove ambiguous/unclear labeling statement.

20. Revise display panel to add:
    - **“Store refrigerated”**  
      → Differentiates from room-temp pemetrexed

21. Add to side panel:
    - **“To Dilute: dilute with 5% Dextrose Injection, USP to achieve a total volume of 100 mL for intravenous infusion.”**

---

If you have any questions, call:

**Rebecca Cohen**  
Regulatory Health Project Manager  
Phone: (240) 402-4998

---

**Sincerely,**  
Joseph Gootenberg, M.D.  
Deputy Director  
Division of Oncology Products 2  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research
```